Business Wire (Thu, 8:30AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,688 people get ACTC.OB articles and Market Currents by email alert.
Get email alerts on ACTC.OB »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 16, 2013)
-
-
-
Business Wire (May 9, 2013)
-
-
-
Business Wire (Apr 23, 2013)
-
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 15, 2013)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Earnings Preview: Pluristem TherapeuticsVytautas Drumelis • Tue, Jun 19, 2012
-
Business Wire (Thu, 8:30AM)
-
Business Wire (May 16, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 15, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Mar 8, 2013)
-
Business Wire (Mar 7, 2013)
-
Business Wire (Mar 4, 2013)
ACTC.OB vs. ETF Alternatives
Company Description
Currently, there's no company description for ACTC.OB.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, March 14, 8:45 AM Advanced Cell Technology (ACTC.OB) receives approval from an independent Data & Safety Monitoring Board to proceed with the next stage of three stem cell studies in the U.S. and Europe in people with the vision disorders Stargardts Macular Dystrophy and dry age-related macular degeneration. The two trials in the U.S. can include patients with better vision than previously allowed. (PR) 4 Comments [Healthcare]
-
- View all 0 replies
-
- View all 3 replies
-
rseiter: This one is called a buy and forget ...it either stays at 8 cents forever, goes to zero or explodes one day when you re not looking -
Noreika: Good point. I need to stop checking every hour before I go crazy. I have my core position, now I need to stop obsessing.
-
- View all 0 replies
-
- View all 16 replies
-
John Motyka: Funk: I subscribe to zmescience. It is Free and most interesting. Lots of breaking news on cutting edge of science projects worldwide...jdm -
-
- View all 0 replies
-
- View all 6 replies
-
John Motyka: Michael: Go to singularityhub.com for free newsletter. Rich source of stem cell news including recent Lancet article plus many others...jdm
-
-
- View all 0 replies
-
- View all 4 replies
-
Funkengruven: I meant to say "hoping" as opposed to "guessing", cuz I believe that is a possibility gbstern.
-
jalphabet: They knew market manipulation would bring it back down along with dilution so sold to reinvest/buyback shares when it really counts. #ACTC
-
John Motyka
What cratered ACTC.OB? Lancet has most promising article about their small trials using donated stem cells. RSVP invited...JDM - View all 11 replies
-
John Motyka: Hey Funk~ You should add ALU to that lineup of 'Sleepers'. All worthy, but still not on fire. The sharks will come around to them too...JDM
-
Funkengruven: Thanks JDM.... Got a small position, thinking about adding if it dips.
-
- View all 5 replies
-
Funkengruven: I'll take good news re 2 patients over nothing... had the stock too long and need something!
-
LATEST REPLIES
-
- View all 3 replies
-
rseiter: This one is called a buy and forget ...it either stays at 8 cents forever, goes to zero or explodes one day when you re not looking
-
Noreika: Good point. I need to stop checking every hour before I go crazy. I have my core position, now I need to stop obsessing.
-
- View all 16 replies
-
John Motyka: Funk: I subscribe to zmescience. It is Free and most interesting. Lots of breaking news on cutting edge of science projects worldwide...jdm
-
-
- View all 6 replies
-
John Motyka: Michael: Go to singularityhub.com for free newsletter. Rich source of stem cell news including recent Lancet article plus many others...jdm
-
-
John Motyka
What cratered ACTC.OB? Lancet has most promising article about their small trials using donated stem cells. RSVP invited...JDM - View all 11 replies
-
John Motyka: Hey Funk~ You should add ALU to that lineup of 'Sleepers'. All worthy, but still not on fire. The sharks will come around to them too...JDM
-
Funkengruven: Thanks JDM.... Got a small position, thinking about adding if it dips.
-
- View all 4 replies
-
Funkengruven: I meant to say "hoping" as opposed to "guessing", cuz I believe that is a possibility gbstern.
-
jalphabet: They knew market manipulation would bring it back down along with dilution so sold to reinvest/buyback shares when it really counts. #ACTC
-
- View all 5 replies
-
Funkengruven: I'll take good news re 2 patients over nothing... had the stock too long and need something!
-
-
Iosonorico
BioTime, Inc. (BTIM-RETIRED) uses ACTC.OB technology to support their R&D efforts (pay attention to page 46) http://bit.ly/7A286 - View all 1 replies
-
-
- View all 3 replies
-
jalphabet: my guess is that something good is imminently going to come from that phase 1/2 stem cell trial. Or, these are leftovers from Geron.
-
-
- View all 3 replies
-
-
-
jalphabet
Leading Eye Institute to Participate in ACTC.OB Embryonic Stem Cell Clinical Trial for Macular Degeneration http://yhoo.it/x6ddrV - View all 1 replies
-
Pancho1901: Just more good news. Reading between the lines, the human trials are working!!
-
- View all 4 replies
-
-
jalphabet: thank you very much for this. its exciting to find other people so excited about this stock